Bonesupport, a Sweden-based developer of injectable bone substitutes to treat orthopaedic trauma and infections backed by pharmaceutical firm Lundbeck, closed a $14m funding round on Wednesday.
The round was led by an unnamed major Scandinavian pension fund, and also featured undisclosed existing investors.
Bonesuppport previously raised SEK 510m ($59.3m) from investors including Lundbeckfond Ventures, the investment arm of drug producer Lundbeck, Industrifonden, HealthCap, Teknoinvest, Vencorp Partners, NBGI Ventures, Ferd Venture and Innovations Kapita.
Founded in 1999 and based on research by Lars Lindgren, professor at Lund University, Bonesupport’s lead product, Cerament is a synthetic bone graft that can be injected under local anaesthesia.
Cerament has been clinically proven to remodel bone within twelve months and is commercially available in both Europe and the US. The latest funding will be used by Bonesupport to support global sales and marketing efforts and further develop the product.